Fig. 3.

Fig. 3.

Long-term vemurafenib drug-pellet treatment causes acquired drug resistance in zebrafish melanoma. (A) Representative images of BRAF^V600E zebrafish melanoma before treatment, regressed melanoma and progressive disease for the animals shown in B. Scale bars: 1 mm. (B) Quantification of melanoma size change each week under treatment with 100 mg/kg or 200 mg/kg vemurafenib pellets after dose escalation. Fish receiving vemurafenib pellets, N=4; lesion count, n=6. Each coloured line represents one lesion, with the size change tracked over the entire treatment course. Lesions from the same fish share the same colour. The representative lesion shown in A is indicated by round dots. (C) Representative images of BRAF^V600E zebrafish melanoma before treatment, during melanoma regression and evidence of recurrent disease while on consistent treatment of 200 mg/kg vemurafenib. Scale bars: 1 mm. (D) Quantification of melanoma size change each week under treatment with 200 mg/kg vemurafenib pellets. Fish receiving vemurafenib pellets, N=6; lesion count, n=14. Each coloured line represents one lesion, with the size change tracked over the entire treatment course. Lesions from the same fish share the same colour. The representative lesion shown in C is indicated by round dots.